Experiments using breast cancer patient-derived xenografts revealed that paclitaxel treatment activates type I IFN and TNFα and that a cGAS-STING-dependent apoptotic effect is required for the paclitaxel response in vivo [39]. The gene discussed is STING1; the disease is breast carcinoma.